Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Robust CD4+ CAR T cell expansion is associated with non-ICANS neurotoxicities after ciltacabtagene autoleucel in patients with multiple myeloma.
Journal: Science translational medicine
Published: July 29, 2026
Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data.
Journal: Clinical pharmacology and therapeutics
Published: February 26, 2026
Lenalidomide-Related Diarrhea in Patients with Multiple Myeloma is Associated with Gut Microbiota Dysbiosis and Disruption of the Bile Acid Pool.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 23, 2026
Pharmacokinetics of CAR T cells in multiple myeloma - the good, the bad, and the ugly.
Journal: Leukemia
Published: January 08, 2026
Robust CD4+ CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene Autoleucel.
Journal: medRxiv : the preprint server for health sciences
Published: November 24, 2025
Mileage matters: long-distance performance of CARs in multiple myeloma.
Journal: Journal for immunotherapy of cancer
Published: October 16, 2025
Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma.
Journal: Blood cancer journal
Published: October 13, 2025
Last Updated: 09/26/2026